This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reymann, M T
Right arrow Articles by Dismukes, W E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reymann, M T
Right arrow Articles by Dismukes, W E

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1979 September; 16(3): 353-361

Correlation of aminoglycoside dosages with serum concentrations during therapy of serious gram-negative bacillary disease.

M T Reymann, J A Bradac, C G Cobbs and W E Dismukes

ABSTRACT

We prospectively evaluated serum aminoglycoside (AMG) concentrations in 120 patients who received gentamicin or tobramycin for serious gram-negative bacillary disease. AMG serum concentrations were assayed by microbiological and radioimmunoassay techniques. Correlation between the two assay methods was good. When AMG doses were based on total body weight, there was no significant correlation between AMG dosage administered and serum concentrations in patients with either normal or abnormal renal function. The use of ideal body weight for calculation of AMG dosage improved this correlation significantly except in hemodialysis patients. AMG-induced nephrotoxicity occurred in 13 patients. No significant association was noted between the occurrence of toxicity and the specific AMG given or with other commonly recognized risk factors. Among study groups, peak AMG serum concentrations failed to exceed the minimal inhibitory concentration of the infecting organism in 17 to 33% of the cases. Serum inhibitory levels of greater than or equal to 1:8 were not associated with improved survival. There was no significant difference in mortality between the gentamicin- and tobramycin-treated groups. We advise base-line serum AMG levels in seriously ill patients with gram-negative bacillary disease and additional bacteriological studies in selected situations.


Antimicrob Agents Chemother. 1979 September; 16(3): 353-361




This article has been cited by other articles:

  • MOORE, R. D., SMITH, C. R., LIPSKY, J. J., MELLITS, E. D., LIETMAN, P. S. (1984). Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides. ANN INTERN MED 100: 352-357 [Abstract]  
  • Lesar, T. S., Rotschafer, J. C., Strand, L. M., Solem, L. D., Zaske, D. E. (1982). Gentamicin Dosing Errors With Four Commonly Used Nomograms. JAMA 248: 1190-1193 [Abstract]